BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eurand Prices Its Initial Public Offering


5/17/2007 9:50:56 AM

MILAN, Italy and DAYTON, Ohio, May 17 /PRNewswire/ -- Eurand, a global specialty pharmaceutical company, announced today the pricing of its initial public offering of 7 million Ordinary Shares at $16.00 per share (before underwriting discounts and commissions). In addition, Warburg Pincus Equity Partners, L.P. and its affiliates, Warburg Pincus Ventures International, L.P. and Gearoid Faherty, Eurand's Chief Executive Officer, have granted the underwriters an option to purchase a maximum of 1.05 million Ordinary Shares to cover over-allotments, if any.

Eurand's Ordinary Shares will trade on the Nasdaq Global Market under the symbol "EURX" and the offering is expected to close on May 22, 2007.

Deutsche Bank Securities Inc. and Lehman Brothers Inc. acted as joint bookrunners and representatives of the underwriters. Banc of America Securities LLC, Lazard Capital Markets LLC and Thomas Weisel Partners LLC acted as co-managers.

The offering of Ordinary Shares is made solely by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained by contacting the prospectus department at (a) Deutsche Bank Securities Inc. by telephone at: 800-503-4611, by email at: prospectusrequest@list.db.com or by mail at: Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311 or (b) Lehman Brothers Inc. by telephone at: 1- 888-603-5847, by email at: qiana.smith@broadridge.com, by mail at: Lehman Brothers, c/o Broadridge, 1155 Long Island Avenue, Edgewood, NY 11717 or by fax at 631-254-7268.

A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Eurand

Eurand is a specialty pharmaceutical company with facilities in Milan and Trieste, Italy; Philadelphia, Pennsylvania and Dayton, Ohio, USA; and Paris, France.

Source: Eurand, Inc.

>>> Discuss This Story



Read at Reuters
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES